QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-cassava-sciences

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cassava Sciences (NASDAQ:SAVA) with a Neutral.

 rodman--renshaw-reiterates-buy-on-cassava-sciences-maintains-107-price-target

Rodman & Renshaw analyst Elemer Piros reiterates Cassava Sciences (NASDAQ:SAVA) with a Buy and maintains $107 price target.

 whats-going-on-with-cassava-sciences-today

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher Monday. Here's what you need to know.

 cassava-sciences-shares-are-trading-higher-today-what-you-need-to-know

Cassava Sciences, Inc. (NASDAQ: SAVA) saw its stock price soar by 15.5% to $27.13, an increase of $3.64, amid rising short inte...

 8-best-performing-small-caps-in-july-find-out-which-stock-jumped-803

Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 ...

 cassava-sciences-announces-expansion-of-open-label-extension-trials-by-up-to-an-additional-36-months-to-provide-participants-the-opportunity-to-continue-on-treatment-if-they-desire-pending-results-of-the-ongoing-phase-3-trials

Ongoing open-label extension trials of simufilam in Alzheimer's disease to be extended by up to an additional 36 months.The...

 cassava-sciences-advances-alzheimers-drug-through-high-stakes-phase-3-trials

Cassava Sciences' Phase 3 trials for Alzheimer's drug simufilam could change treatment standards. With trials costing m...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION